| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.18 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.2 |